Last reviewed · How we verify
Zurampic (LESINURAD)
At a glance
| Generic name | LESINURAD |
|---|---|
| Sponsor | Ironwood Pharms Inc |
| Drug class | Urate Transporter 1 Inhibitor |
| Target | Solute carrier family 22 member 11 |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
| First approval | 2015 |
Approved indications
- Hyperuricemia
Common side effects
Key clinical trials
- A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment (PHASE4)
- Post-Authorisation Safety Study of Lesinurad
- Lesinurad/Allopurinol 200/300 Fixed-Dose Combination (FDC) Tablets Bioequivalence. (PHASE1)
- Lesinurad and Febuxostat Combination Extension Study in Gout (PHASE3)
- Lesinurad/Allopurinol 200/300 FDC Tablets Bioequivalence (PHASE1)
- Allopurinol Combination Study (PHASE2)
- Lesinurad and Allopurinol Combination Extension Study in Gout (PHASE3)
- Lesinurad/Allopurinol 200/300 FDC Tablets Bioavailability (PHASE1)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zurampic CI brief — competitive landscape report
- Zurampic updates RSS · CI watch RSS
- Ironwood Pharms Inc portfolio CI